Free Trial

Equillium (EQ) Stock Price, News & Analysis

-0.03 (-3.62%)
(As of 09:45 AM ET)
Today's Range
50-Day Range
52-Week Range
7,100 shs
Average Volume
319,086 shs
Market Capitalization
$29.99 million
P/E Ratio
Dividend Yield
Price Target

Equillium MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
342.0% Upside
$3.90 Price Target
Short Interest
1.82% of Float Sold Short
Dividend Strength
News Sentiment
-0.50mentions of Equillium in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$8,700 Sold Last Quarter
Proj. Earnings Growth
From ($0.12) to ($0.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.90 out of 5 stars

Medical Sector

552nd out of 901 stocks

Pharmaceutical Preparations Industry

263rd out of 426 stocks

EQ stock logo

About Equillium Stock (NASDAQ:EQ)

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

EQ Stock Price History

EQ Stock News Headlines

Equillium, Inc. (NASDAQ:EQ) Short Interest Update
Nvidia’s Quiet $1 Trillion Pivot
Nvidia recently added $277 billion in market cap … IN ONE DAY.
Nvidia’s Quiet $1 Trillion Pivot
Nvidia recently added $277 billion in market cap … IN ONE DAY.
See More Headlines
Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$37.89 million
Book Value
$0.64 per share


Free Float
Market Cap
$31.11 million
Not Optionable
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Daniel Mark Bradbury (Age 63)
    Executive Chairman
    Comp: $158k
  • Mr. Bruce D. Steel C.F.A. (Age 58)
    Co-Founder, President, CEO & Director
    Comp: $779.87k
  • Ms. Christine Zedelmayer M.B.A. (Age 54)
    P.M.P., Senior VP & COO
    Comp: $553.73k
  • Dr. Stephen Connelly Ph.D. (Age 42)
    Chief Scientific Officer & Director
    Comp: $571.32k
  • Mr. Jason A. KeyesMr. Jason A. Keyes (Age 53)
    Chief Financial Officer
  • Penny Tom
    Senior VP of Finance & Principal Accounting Officer
  • Mr. Michael Moore
    Vice President of Investor Relations & Corporate Communications
  • Dr. Matthew Ritter Ph.D.
    Senior Vice President of Corporate Development
  • Mr. Joel M. Rothman (Age 55)
    Chief Development Officer
  • Dr. Maple Fung M.D.
    Chief Medical Officer

EQ Stock Analysis - Frequently Asked Questions

How have EQ shares performed this year?

Equillium's stock was trading at $0.7230 at the beginning of the year. Since then, EQ shares have increased by 22.0% and is now trading at $0.8824.
View the best growth stocks for 2024 here

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) posted its earnings results on Thursday, May, 9th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $10.69 million for the quarter, compared to the consensus estimate of $9.15 million. Equillium had a negative trailing twelve-month return on equity of 51.20% and a negative net margin of 32.01%.

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EQ) was last updated on 7/25/2024 by Staff

From Our Partners